| |
Molnupiravir for the Treatment of COVID-19 in
Immunocompromised Patients: Efficacy, Safety,
and Virology Results from the Phase 3 MOVe-OUT Trial
|
| |
| |
Presented at the 32nd European Congress of Clinical
Microbiology & Infectious Diseases (ECCMID); Lisbon, Portugal; April 23-26, 2022
Matthew G. Johnson1; Julie Strizki1; Michelle L. Brown1; Ying Zhang1; Hong Wan1; Hala H. Shamsuddin1; Moti Ramgopal2; Diana F. Florescu3; Pierre Delobel4; Ilsiyar Khaertynova5; José Flores6; Leon F. Fouche7; Shan-Chwen Chang8; Angela Williams-Diaz1; Jiejun Du1;
Jay A. Grobler1; Amanda Paschke1; Carisa De Anda1
1Merck & Co., Inc., Kenilworth, NJ, USA; 2Midway Immunology and Research Center, Fort Pierce, FL, USA; 3University of Nebraska Medical Center, Omaha, NE, USA; 4Université Toulouse III Paul Sabatier, CHU de Toulouse, Toulouse, France; 5Republican Clinical Infectious Diseases Hospital n.a. A.F. Agafonov, Kazan, Russian Federation; 6Clinica Privada Dr. José Francisco Flores López, Guatemala, Guatemala; 7Limpopo Clinical Research Initiative, Thabazimbi, South Africa; 8National Taiwan University Hospital, Taipei, Taiwan
|
|
| |
| |
|
|
|
